Insights

Why Moderna Stock Swooned Today

What happened
Frequently high-flying coronavirus stock Moderna (NASDAQ: MRNA) plunged groundward Wednesday, although this had basically nothing to do with the ongoing pandemic or any operational issues at the company. Rather, it was due to some disquieting personnel news, following which investors traded the stock down by nearly 7% on the day.
So what
That morning, Moderna revealed that its new CFO is now its ex-CFO. Jorge Gomez, who only started his tenure on Monday, has “departed” from his new employer. The move is effective immediately, and it comes a day after his previous company Dentsply Sirona (NASDAQ: XRAY) publicly disclosed “an ongoing internal investigation into certain matters, including financial reporting.”
It is not clear whether Gomez is, or will be, a focus of that investigation.
Image source: Getty Images.

Gomez, whose appointment was announced by Moderna exactly one month ago, was replaced by his predecessor David Meline on an interim basis, effective Wednesday. The seemingly departing CFO, who was entering retirement, was to serve as a consultant during a transitional period as his replacement settled into the job.
This is an embarrassing development for Moderna, particularly since Gomez’s credentials seemed solid. In addition to his stint as CFO at Dentsply Sirona, a dental products maker, he worked at healthcare services mainstay Cardinal Health, most recently as its CFO. He also currently serves on the board of directors of Xylem and Pear Therapeutics.
Now what
Moderna said little else in its tersely worded press release on the matter besides the raw facts of Gomez’s departure, the reason for it, and the reinstallment of Meline. Since Gomez’s tenure at Moderna was extremely short, I don’t think there will be too much lasting blowback on the company no matter how the Dentsply Sirona investigation goes. Still, investors would be wise to monitor developments in that situation.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy. –

What happened

Frequently high-flying coronavirus stock Moderna (NASDAQ: MRNA) plunged groundward Wednesday, although this had basically nothing to do with the ongoing pandemic or any operational issues at the company. Rather, it was due to some disquieting personnel news, following which investors traded the stock down by nearly 7% on the day.

So what

That morning, Moderna revealed that its new CFO is now its ex-CFO. Jorge Gomez, who only started his tenure on Monday, has “departed” from his new employer. The move is effective immediately, and it comes a day after his previous company Dentsply Sirona (NASDAQ: XRAY) publicly disclosed “an ongoing internal investigation into certain matters, including financial reporting.”

It is not clear whether Gomez is, or will be, a focus of that investigation.

Image source: Getty Images.

Gomez, whose appointment was announced by Moderna exactly one month ago, was replaced by his predecessor David Meline on an interim basis, effective Wednesday. The seemingly departing CFO, who was entering retirement, was to serve as a consultant during a transitional period as his replacement settled into the job.

This is an embarrassing development for Moderna, particularly since Gomez’s credentials seemed solid. In addition to his stint as CFO at Dentsply Sirona, a dental products maker, he worked at healthcare services mainstay Cardinal Health, most recently as its CFO. He also currently serves on the board of directors of Xylem and Pear Therapeutics.

Now what

Moderna said little else in its tersely worded press release on the matter besides the raw facts of Gomez’s departure, the reason for it, and the reinstallment of Meline. Since Gomez’s tenure at Moderna was extremely short, I don’t think there will be too much lasting blowback on the company no matter how the Dentsply Sirona investigation goes. Still, investors would be wise to monitor developments in that situation.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!